OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Portfolio Pulse from
OPKO Health and Entera Bio have entered a collaboration to develop an oral GLP-1/glucagon tablet for treating obesity and metabolic disorders. The program combines OPKO's oxyntomodulin analog and Entera's N-Tab technology, with plans to file an IND with the FDA this year.
March 17, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Entera Bio is collaborating with OPKO Health to develop an oral GLP-1/glucagon tablet using its N-Tab technology. An IND filing with the FDA is anticipated this year.
Entera Bio's collaboration with OPKO Health to develop a new treatment for obesity and metabolic disorders could enhance its technological application and market reach. The anticipated IND filing with the FDA suggests advancement towards clinical trials, likely to positively impact investor sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
OPKO Health is collaborating with Entera Bio to develop an oral GLP-1/glucagon tablet for obesity treatment, leveraging its oxyntomodulin analog. An IND filing with the FDA is expected this year.
The collaboration with Entera Bio to develop a novel treatment for obesity and metabolic disorders could enhance OPKO Health's product pipeline and market position. The expected IND filing with the FDA indicates progress towards clinical trials, potentially boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80